Torrey Pines Investment
VC Fund
San Diego, United States
Torrey Pines Investment is a VC fund in San Diego focused on Biotechnology and Health Care. Torrey Pines Investment, founded in 2002, is a specialty life-science investment company located in San Diego.Torrey Pines has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has created biopharma incubators investing in early development stage assets from internationalpharma and biotech partners in CNS, oncology, and virology areas to bring them to commercial success through pharma partnering and M&A.We are committed to capitalizing on the unique opportunities in biotech and pharma, where we can add value in development or regulatory strategy by utilizing resources of our portfolio CRO companies. We seek to leverage our industry knowledge, network of industry and financial contacts, and internal resources to assist our portfolio management in developing and executing their business strategy. Our bottom line is to help our companies achieve growth, build value and realize wealth.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 19%
- Fund size:
- $60M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Torrey Pines Investment invests in
Stages Torrey Pines Investment invests in
Countries Torrey Pines Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $3M–$3.1M
Investment Focus
Industry
- Biotechnology 12 (38%)
- Health Care 8 (25%)
- Pharmaceutical 7 (22%)
- Medical 4 (13%)
- Life Science 3 (9%)
Stage
- Seed 13 (41%)
- Funding Round 7 (22%)
- Pre-Seed 3 (9%)
- Series A 2 (6%)
- Series B 1 (3%)
Country
- United States 17 (53%)
- Russian Federation 3 (9%)
- The Netherlands 2 (6%)
- Canada 1 (3%)
- Zambia 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ronald Demuth
President
|
President | Total investments: 0 | Find email | |
Steve Adler
CEO and VP Business Development
|
CEO and VP Business Development | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mondego Bio
|
Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. | Series A / Sep 18, 2025 | |
Mair Therapeutics
|
Mair Therapeutics main goal is finding and creating a small-molecule ion channel activator to treat Parkinson's disease, a preclinical drug discovery business. | Pre-Seed / Feb 13, 2025 | |
MAIR PHARMACEUTICALS
|
Mair Pharmaceutical creates innovative processes and produces well-known unique substances for pharmaceutical and biopharmaceutical firms worldwide. | Pre-Seed / Feb 13, 2025 | |
Lomond Therapeutics
|
Lomond Therapeutics is a pharmaceutical firm that discovers and develops small molecule inhibitors that target escape variants in hematologic malignancies. | $44M / Venture - Series Unknown / Nov 04, 2024 | |
|
Lomond Therapeutics
|
Lomond Therapeutics is a pharmaceutical firm that discovers and develops small molecule inhibitors that target escape variants in hematologic malignancies. | $44M / Post-IPO Equity / Nov 04, 2024 | |
Polku Therapeutics
|
Polku Therapeutics operates as a therapeutics company. Polku Therapeutics develops novel disease-halting therapies which provides new treatment options. | $2M / Pre-Seed / Sep 17, 2024 | |
Brenig Therapeutics
|
Brenig Therapeutics develops therapies for neurodegenerative disorders. | $65M / Series A / Jul 24, 2024 | |
|
i2020 Accelerator
|
The i2020 Accelerator will provide funding and resources to companies in the areas of inflammation, oncology, CNS, and infectious diseases | Seed / Jan 01, 2019 | |
Context Therapeutics
|
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Contextis advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1. | Nov 15, 2017 | |
Viriom
|
Viriom Inc. is a development and commercial stage biotech company developing novel and affordable medicines against life threatening infections such as HIV and HBV. The company has an exclusive worldwide license to its phase 3 and commercial stage lead compounds (Elpida/elsulfavirine and VM1500A) from Hoffmann-La Roche and has developedproprietary drug candidates VM2500, VM3500 LAI formulations and combinations with cell, vaccine and antibody drugs for treatment, prophylaxis and cure of HIV. Viriom makes a breakthrough in treating, preventing and curing HIV and chronic HBV infections worldwide. | $2.6M / Convertible Note / Jun 06, 2017 | |
| See all 32 investments → | |||
Co-Investors
OrbiMed
4 deals together
Biovance Capital
3 deals together
American Financial Group
2 deals together
Avalon Ventures
2 deals together
Deerfield Management
2 deals together
Heights Capital Management
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Torrey Pines Investment invest in?
Torrey Pines Investment invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Funding Round stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Torrey Pines Investment's check size?
Torrey Pines Investment typically joins rounds of $3M–$3.1M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Torrey Pines Investment participates in.
How do I contact Torrey Pines Investment?
Public channels for Torrey Pines Investment include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Torrey Pines Investment?
The team at Torrey Pines Investment includes Ronald Demuth (President) and Steve Adler (CEO and VP Business Development). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
